PXS Insider Trading

Insider Ownership Percentage: 17.33%
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Pharmaxis Insider Trading History Chart

This chart shows the insider buying and selling history at Pharmaxis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pharmaxis Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for PXS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Pharmaxis Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/29/2023Gary PhillipsInsiderIssued2,771,000A$0.03A$83,130.00
12/2/2022Kathleen MettersInsiderIssued3,000,000A$0.06A$189,000.00
11/29/2022Gary PhillipsInsiderIssued2,771,000A$0.06A$174,573.00
11/1/2022Gary PhillipsInsiderBuy1,640,450A$0.06A$103,348.35
8/22/2022Gary PhillipsInsiderExpiry1,305,700A$0.08A$100,538.90
12/22/2021Malcolm McComasInsiderIssued285,715A$0.11A$30,000.08
11/3/2021Gary PhillipsInsiderIssued2,374,000A$0.12A$273,010.00
8/12/2021Gary PhillipsInsiderExpiry471,000A$0.10A$44,745.00
See Full Table

SEC Filings (Institutional Ownership Changes) for Pharmaxis (ASX:PXS)

37.48% of Pharmaxis stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Pharmaxis logo
Pharmaxis Ltd, a clinical stage drug development company, engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. It operates through Mannitol Respiratory Business and New Drug Development segments. The company provides Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, a lung function test for the treatment of asthma. It's product pipeline comprises oral pan-Lysyl Oxidase Inhibitors (LOX) targeting myelofibrosis and other cancers; topical pan-LOX inhibitors targeting skin scarring after events such as accidents, surgery, and burns; selective Lysyl Oxidase Like Inhibitors (LOXL2) targeting chronic fibrotic diseases including kidney, pulmonary, liver, and cardiac fibrosis; and semicarbazide-sensitive amine oxidase for neuro inflammatory diseases. The company also offers Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
Read More on Pharmaxis

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

721,139 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

6.41%

Beta

0.64

Who are the company insiders with the largest holdings of Pharmaxis?

Pharmaxis' top insider investors include:
  1. Gary Phillips (Insider)
  2. Kathleen Metters (Insider)
Learn More about top insider investors at Pharmaxis.